Actively Recruiting
Genetic Risks for Childhood Cancer Complications in Switzerland
Led by University Hospital, Geneva · Updated on 2021-01-13
6000
Participants Needed
1
Research Sites
891 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objectives of the GECCOS project are to identify genetic variants associated with complications of childhood cancer using genotype-phenotype association studies. Germline genetic samples and data of the "Germline DNA Biobank for Childhood Cancer and Blood Disorders Switzerland" (BISKIDS) which is included in the Geneva Biobank for Hematology and Oncology in Pediatrics (BaHOP) will be used with clinical data of Swiss childhood cancer patients collected at the Institute of Social and Preventive Medicine in Bern.
CONDITIONS
Official Title
Genetic Risks for Childhood Cancer Complications in Switzerland
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Registered in the Swiss Childhood Cancer Registry (SCCR) since 1976
- Consented to the BaHOP biobank for the BISKIDS project
- Diagnosed with cancer according to the International Classification of Childhood Cancer, version 3 (ICCC-3), or Langerhans cell histiocytosis (LCH) before age 21 years
You will not qualify if you...
- Missing written consent signed by participant or legal representative to participate in BaHOP
- Died after study participation and declined use of their samples and data after death in the original BaHOP consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital of Geneva
Geneva, Switzerland, 1211
Actively Recruiting
Research Team
M
Marc Ansari, Prof
CONTACT
N
Nicolas Waespe, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here